Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Summary

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.

Timeline

Start

2010-12-06

Primary completion

2014-03-03

Completion

2016-12-20

Outcome

Missed primary endpoint

paper Axitinib/BSC did not improve OS over placebo/BSC in the overall population or in stratification subgroups. PMID 26386123 ↗

Publications

• Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015 Dec;26(12):2457-63. doi: 10.1093/annonc/mdv388. Epub 2015 Sep 18.

Drugs

Indications